In the second part of this podcast, haematologist and clinical researcher Dr Phillip Thompson talks about the rapidly evolving area of treatment for relapsed/refractory CLL after chemo-immunotherapy. Dr Thompson says it is important to re-evaluate a person’s genomic characteristics after a relapse and the overall approach is to use novel agents rather than repeat chemo-immunotherapy. ...
Episode 2: The changing therapeutic landscape for R/R CLL, with Dr Phillip Thompson
17 Dec 2019
Sponsored by Janssen-Cilag Pty Ltd